Insulin glulisine

 Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[4] It was developed by Sanofi-Aventis and is sold under the trade name Apidra.[5] When injected subcutaneously, it appears in the blood earlier than human insulin.[6] When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.[7] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[2]

Insulin glulisine
Insulin glulisine 6GV0 cartoon.png
PDB: 6gv0​
Clinical data
Trade namesApidra, Apidra SoloStar
AHFS/Drugs.comMonograph
MedlinePlusa607033
License data
  • EU EMA: by INN
  • US DailyMed: Insulin_glulisine
Pregnancy
category
  • AU: B3[1]
Routes of
administration		Subcutaneous, intravenous
ATC code
  • A10AB06 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only [2]
  • EU: Rx-only [3]
Identifiers
CAS Number
  • 207748-29-6 ☒
DrugBank
  • DB01309 check
ChemSpider
  • none
UNII
  • 7XIY785AZD
KEGG
  • D04540 check
Chemical and physical data
FormulaC258H384N64O78S6
Molar mass5822.64 g·mol−1
 ☒check (what is this?)  (verify)

The most common side effects include hypoglycaemia (low blood glucose levels).[3]

Medical usesEdit

Insulin glulisine is indicated for the treatment of diabetes mellitus.[3][2]

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.